MerabDvalishvili can joke about his low finishing rate in theUltimate Fighting Championship.

Dvalishvili is scheduled to challenge Petr Yan forthe bantamweight ******* le in a trilogy bout at UFC 333 on Oct. 24 at Etihad Arena in Abu Dhabi. When a fanrecently asked him to predict the outcome, the former championjokingly suggested another decision victory.
Dvalishvili is known for his relentless pressure and wrestling,with 16 of his 21 career victories coming by decision. The Georgianhas recorded two finishes in the UFC: a technical knockout ofMarlonMoraes in 2021 and a submission of SeanO'Malley in his second ******* le defense last year.

Asked how he would beat Yan, Dvalishvili described himself as a"decision machine."

"There are three ways to win: knockout, submission, or decision,"Dvalishvili said in a briefinterview. "I'm a decision machine."

#machine #championship

A complaint has been filed against PETA for allegedly being involved in a political agenda, especially towards Prince William and Kate Middleton, contrary to its fundamental purpose.
The group, which previously targeted Wales, King Charles, and the Archbishop of Canterbury, is now under scrutiny for its campaigning activities.
Meanwhile, speculation swirls around William and Prince Harry's future, with reports of a service honoring Princess Diana's legacy raising the possibility of a reunion between the brothers.
ZUMAPRESS.com / MEGA
PETA Watch has now filed a submission with the Charity Commission alleging that the animal rights group has turned away from its charitable mission and become increasingly involved in political activism.

#peta #involved #group #middleton

Jose Delgado will be back.
The rising Ultimate Fighting Championship (UFC) Featherweight prospect suffered a third-round submission loss to top Brazilian contender Jean Silva in the main event of Noche UFC 4 this past weekend (Sat., Sept. 12, 2026) inside Desert Diamond Arena in Glendale, Arizona (watch highlights).
Delgado accepted the biggest opportunity of his career on approximately three weeks' notice, replacing former interim Featherweight champion Yair Rodriguez and headlining a UFC event in front of his hometown crowd.
After taking a day to gather his thoughts, Delgado released a statement addressing the first main event loss of his UFC career.
"Well, ***** , so it goes," Delgado wrote on Instagram. "Dared to be great yesterday and came up short. But man, I loved every second of being on that stage with high-level opposition; that includes the heartbreaking pain of failure. Pure freedom. Insert something cliche about bouncing back here. Thank you to God for His guidance and my village for backing me. Also, thanks to everyone in that arena for making that walk what it was. Love y'all."

#main

Jean Silva had to push through some early adversity earlier tonight (Sat., Sept. 12, 2026) at Noche UFC 4 LIVE on Paramount+ from inside Desert Diamond Arena in Glendale, Arizona, but the featherweight powerhouse eventually scored a main event submission finish over Jose Delgado (see it HERE).
In addition to the featherweight headliner, Noche UFC 4 produced a long list of memorable performances, highlight-reel finishes, and exciting wars. Take a look at the key moments below and let us know who stood out the most!
Sean King III delivered the goods in his Octagon debut with a monstrous knockout slam just 36 seconds into the fight (see it HERE)
Undefeated lightweight Tommy Gantt captured the biggest win of his career so far with a reverse triangle choke against veteran Drakkar Klose
Alex Pereira's training partner, former kickboxing standout Yousri Belgaroui, pushed his UFC record to 3-0 with a nasty TKO stoppage (highlights HERE)

#noche #featherweight

Jean Silva may have started slow but his aggression finally came through as he dropped Jose Miguel Delgado and finished with a one-arm rear-naked choke in the Noche UFC main event.
At the start of the fight, Silva just put his fists out and circled the octagon but once he got moving, he was hurting Delgado with a variety of strikes. Finally in the third round, Silva put Delgado against the cage and unloaded a huge shot that dropped his opponent to the canvas.
JEAN SILVA GETS THE CHOKE!!

📺 paramountplus pic.twitter.com/2VAPtWrpb5
A moment later, Silva was on his back and ****** ing the submission with Delgado tapping out at 2:57 in the third round to end the fight. Silva has now won two fights in a row and it's no secret what he wants next.
"This is for you guys," Silva said to the Arizona crowd. "This is the show I bring in for you guys. No animosity from me. This is for you and you deserve this.

#finally #dropped #round #guys

Tommy McMillen vs. Marwan Rahiki squared off in a Featherweight bout earlier this morning (Sat., Sept. 12, 2026) inside Desert Diamond Arena in Glendale, Arizona for Noche UFC 4. After a wild and ****** fight, McMillen was named the victor.
McMillen opened the fight with an overhand right and a surprising takedown. He tried to threaten an arm triangle, but Rahiki quickly escaped to his feet. Back in the standup, the two wasted little time in throwing powerful punches. The range widened, and the two young Featherweights traded kicks. Rahiki got on the front foot and put his opponent on the defensive. His chin was really high though …
Rahiki hit the body and timed a gorgeous right hand. McMillen tied together his kicks and punches, opening a small cut by Rahiki's eye. Two hard right hands connected for McMillen, but "Freaky" fired right back. At the close of the competitive opening round, the two mouthed off at one another as the referee kept them apart.
McMillen was active to start round two, throwing a lot of volume and landing a particularly stiff jab. McMillen threatened a guillotine choke to gain top position but couldn't hold down Rahiki. Rahiki kicked the calf and then started ripping the body to great effect. McMillen's nose was bleeding, but he scored a heavy left hand that wobbled his opponent briefly.
Out of nowhere, a Rahiki counter uppercut floored McMillen! Rahiki turned up the offense and landed a bunch of cracking shots. Somehow, McMillen was able to survive and even land a big right hand of his own a minute later. McMillen started to build some offense on his fatigued opponent, including a late takedown that saw him finish the round with some submission attempts.

#round

A massive brawl has erupted at ADCC 2026, involving Dorian Olivarez and his famous teammate and coach, Gordon Ryan.
One of the 66 kg tournament favorites in Olivarez finished Bezkat Kapashov in the opening round of a Brazilian jiu-jitsu (BJJ) match that was extra chippy and physical. Tensions flared immediately after the submission, with a pretty large Kazakh team contingent confronting Olivarez and his cornermen.
Things quickly escalated to a pretty sizable brawl involving Ryan, Olivarez and the Kapashov's entire team. Ryan was eventually seen on the ground and taking punches while going against three men in a chaotic scene.
ADCC officials eventually pulled people off him to de-escalate the situation, and the scuffle was eventually diffused after a minute. Fortunately, no one seemed to have been seriously hurt.
Olivarez will be able to continue onto the next round. Ryan was seen throwing a thumbs up towards officials as he just immediately went back to his chair on the next mat, as one of his many teammates on the card was still competing.

#eventually #adcc #involving #pretty

Hole-in-one: Brentwood ― Leela Clark, No. 5, 111 yards, 9-iron.
How to report results
The Times-Union accepts submissions for holes-in-one, eagles on par-4 holes, double-eagles, matching or beating your age, course records and career lows. Tournament results accepted are areawide events, club, and men's and women's ****** ociations. Calendar items may include charitable events. Results must contain first and last names, scores (indicating gross or net) and the format. Email submissions to gsmitsgannett.com.
Sept. 4-6: Junior Players Championship, Players Stadium Course at TPC Sawgrass. Visit ajga.org.
Sept. 5-6: Walker Cup, Lahinch Golf Club, Ireland.

#course #Eagles #Events

"I don't think you can deny me much longer and I think people will see that soon."
Those are the confident words of Wrexham native Ieuan Davies who has his sights firmly fixed on the UFC.
And with the start he has made to his professional mixed martial arts career, there is no reason he should not feel confident.
The 30-year-old captured the Cage Warriors lightweight ***** le in sublime fashion in June as he stopped Omiel Brown in just 61 seconds with a rear naked choke.
It was the sixth submission victory of the Welshman's career and one he hopes caught UFC president Dana White's eye.

#davies #june

Where to watch ADCC World Championships: Full schedule, times, live stream, channel for 2026 grappling event originally appeared on The Sporting News. Add The Sporting News as a Preferred Source by clicking here.
For the first time, Poland will host the ADCC World Championships this weekend.
The world's best submission grapplers compete for the ultimate bragging rights. The ADCC World Championships feature athletes competing across multiple men's and women's weight classes, as well as the absolute division.
Micael Galvao, one of the most exciting grapplers today, won a 77kg ***** le in 2024. Other top grapplers and former champions at the event include Felipe Pena, Dante Leon, Helena Crevar, and more.
Here is everything you need to know about the ADCC World Championships, including TV and streaming options for the tournament.

#sporting

Below are the stat leaders from across the Houston high school football scene, compiled through MaxPreps and coach submissions. ***** ulative season stats and any updates, corrections or additions can be sent to jpoormanhoustonchronicle.com.
Note: Players whose stats are not updated through the current week are not included.
There's more to Houston with the Chronicle. Subscribe today for just 25¢.
This article originally published at Texas high school football: Houston-area stat leaders after Week 2.

#week #stat #Football

On August 5, OraSure Technologies (NASDAQ:OSUR) reported second-quarter 2026 results that included its first GAAP net income in years, a headline number of $6.2 million versus a $19.7 million loss a year earlier. Revenue of $30.6 million beat the company's own guidance range and climbed 9.7% from the prior quarter. But look past the top line and the story splits in two, one part driven by real operating progress, the other by an accounting adjustment tied to a regulatory setback.
Some of this quarter's improvement came from actual operations. Gross margin expanded to 43.5% on a GAAP basis, up from 42.1% a year earlier, and non-GAAP gross margin rose to 44.2% from 43.2%. Diagnostics revenue grew 1% year over year to $19.4 million, helped by higher syphilis test sales and the addition of BioMedomics' Sickle SCAN product line. OraSure also picked up two regulatory wins during the quarter. In June 2026, the FDA cleared its Colli-Pee Dx urine collection kit for use with Roche's **** ually transmitted infection tests, letting patients collect samples at home instead of in a clinic.
The following month, the FDA granted Emergency Use Authorization for the second-generation OraQuick Ebola 2.0 Rapid Antigen Test, which can detect all four Ebola virus strains known to cause disease in humans. Cash used in operating activities improved to $23.8 million over the first six months of 2026, down from $30 million a year earlier, a sign the cash burn is easing. The company also kept buying back stock, repurchasing $22 million of shares, or 7.7 million shares, against its $40 million authorization, retiring more than 10% of shares outstanding.
The GAAP profit that headlines this quarter didn't come from the business getting more profitable. It came almost entirely from a $22.6 million reduction in a contingent consideration liability, an accounting entry triggered when OraSure updated its regulatory submission plan for the CT/NG test on its Sherlock platform. Strip that adjustment out and the underlying trend looks different. Non-GAAP operating loss widened to $14.7 million from $13.2 million a year earlier, and non-GAAP net loss came in at $13.8 million, roughly in line with last year's $14.2 million loss. The regulatory event behind that accounting gain is itself a setback.
In July, OraSure withdrew its InteliQuick CT/NG molecular self-test submission after receiving FDA feedback, meaning the product's path to market is now delayed while the company prepares a future resubmission. Total revenue for the quarter was still down 2% year over year, and core revenue, which excludes COVID-19 and Risk **** sment Testing, was flat. Six-month revenue fell 4% to $58.6 million. Sample Management Solutions revenue stayed flat year over year at $9.9 million, showing no growth driver of its own. Cash and equivalents fell to $161 million at quarter-end from $199.3 million at the end of 2025, pulled down by continued buybacks and cash used in operations.

#year #gaap #reven

Our ***** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Research publishing momentum is driven by record submission levels, up 31%, and a widening scale advantage that management believes creates a structural moat for large-scale publishers.
The 'Wiley Flywheel' strategy integrates proprietary research content with AI and data ***** ytics, where publishing fuels AI training and AI tools subsequently increase researcher productivity.
AI revenue growth is shifting toward a more favorable mix, with recurring revenue growing 2x to 3x over the prior year as the company expands beyond life sciences into chemistry and finance.
The Emerald acquisition is performing ahead of schedule, providing immediate scale in business and finance disciplines while contributing to research margin expansion through early cost synergies.

#Research #finance #NVIDIA #tell

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
The U.S. ETF industry is pushing back against the Securities and Exchange Commission's (SEC) broad review of "novel ETFs."
ETF professionals argue an overly wide definition could slow product launches and undermine one of the market's biggest advantages, even as increasingly complex funds test the boundaries of the traditional ETF structure, per a Reuters report.
The SEC opened the review in June after delaying a wave of proposed prediction-market ETFs. Its request covers ETFs that invest in innovative ***** et classes or use unconventional strategies and asks whether existing rules adequately address investor protection, market integrity, and the registration process.
More than 20 industry participants submitted comments around the Aug. 31 deadline, with the docket showing submissions from Charles Schwab, Franklin Templeton, Jane Street, Cboe Global Markets, Grayscale Investments, 21Shares, Andreessen Horowitz and Kalshi.

#industry #finance #securities #june

On August 3, Ocular Therapeutix (NASDAQ:OCUL) reported second-quarter 2026 financial results that read as much like a regulatory update as an earnings report. Management confirmed that AXPAXLI, its lead retinal disease candidate, remains on track for a new drug application submission for wet age-related macular degeneration in the fourth quarter of 2026, a plan the FDA effectively signed off on during a Type C meeting held in May. That timeline, paired with new data suggesting patients could need far fewer injections, is the headline. The rest of the report shows what it costs to get there.
AXPAXLI's case rests on the SOL-1 trial, which Ocular describes as the first successful superiority study of a new agent against an approved anti-VEGF therapy since that drug class arrived two decades ago. The FDA's May 2026 meeting minutes confirmed that SOL-1's efficacy and safety data, along with an interim safety look at the SOL-R trial and supporting evidence on axitinib, will be enough to support the NDA filing, and Ocular plans to file under the 505(b)(2) pathway, which could shave up to 60 days off a standard review.
A post hoc ***** ysis of SOL-1 adds a practical argument for the drug: applying SOL-R's stricter rescue criteria, Ocular estimates patients could need up to 72% fewer injections through 60 weeks, or 56% once the two loading doses are counted, than a patient on a typical every-eight-week aflibercept regimen, a gap that matters given that up to 40% of wet AMD patients quit treatment within their first year.
Early market research backs that pitch: about 80% of surveyed retina specialists said they would likely prescribe a drug with AXPAXLI's profile, and more than 90% expect to adopt it within a year of approval. The company says every Tier 1 payer it has engaged, across Medicare Advantage and commercial plans, has floated premium pricing for a more durable option. Underpinning all of it is a cash balance of $598.6 million as of June 30, which management expects to last into 2028.
Getting AXPAXLI to market is expensive, and the quarter showed it. Research and development spending rose to $54.1 million from $51.1 million a year earlier, selling and marketing costs climbed to $17.3 million from $13.7 million, and general and administrative expenses jumped to $22.2 million from $14.3 million, all tied to trial costs and a growing commercial team ahead of a launch that still is not approved. Net loss widened to $78.8 million from $67.8 million in the same quarter of 2025.

#quarter #costs

On August 25, Electromed (NASDAQ:ELMD) reported fiscal fourth-quarter results that extended a streak few small-cap medical device companies can claim: fifteen consecutive quarters of year-over-year revenue and profit growth. Net revenue hit a record $19.4 million, up 11.6% from a year earlier, and diluted earnings per share climbed to $0.39 from $0.25. Those headline numbers look clean, but they arrive alongside a leadership change and a hospital business moving in the opposite direction, which makes the quarter more complicated than the growth streak suggests.
Home care is still the whole story here. Home care revenue reached $17.7 million in the quarter, up 15.2% year over year, and for the full fiscal year it grew 16.3% to $66.6 million. That growth is coming from efficiency, not just headcount: on an annualized basis, home care revenue worked out to $1,145,000 per rep, above the company's own target range of $1 million to $1.1 million. Electromed ended the year with 64 direct sales reps and is targeting 67 filled territories for fiscal 2027, including two hospital account liaisons meant to catch patients as they move from acute care into home-based therapy.
The addressable market behind that growth still looks large. Management estimates roughly 1 million people in the U.S. carry a bronchiectasis diagnosis, yet only about 16% currently use high-frequency chest wall oscillation therapy, leaving close to 800,000 diagnosed patients untreated, plus more than 4 million additional people who may have the condition without a diagnosis at all. Payer access has kept pace with that opportunity.
Electromed closed the fiscal year with 87% of US covered lives under contract after signing 40 new payer agreements and adding 6 million covered lives. Its Smart Order e-prescribing tool handled 45% of fourth-quarter orders and shipped them noticeably faster than fax submissions, which matters as CMS rules phase out fax-based ordering by May 2028. All of this sits on a debt-free balance sheet, with cash growing to $20.5 million even after $3.9 million in share repurchases during the year.
The weaker spots are easy to miss next to those numbers. Hospital revenue fell 29% in the fourth quarter, which CEO James Cunniff attributed to a sales cycle that is "inherently less predictable than our other channels." The distributor channel grew just 2% in the quarter, and combined, the non-home care business grew only 6.7% for the full year versus 16.3% in home care, meaning nearly all of Electromed's growth is coming from one channel. SG&A expenses rose 8.7% to $42.7 million for the year, driven mainly by higher sales, marketing, and reimbursement compensation, and accounts receivable climbed to $29.8 million from $24.7 million as the business scaled up.

#quarter #Growth #electromed #hospital

Silvestre Sanchez may have punched his way to a UFC deal.
At Dana White's Contender Series 90 on Tuesday, Mexico's Silvestre (10-1) proved the oddsmakers wrong as he finished England's Liam McCracken (8-2) with a big left hook to close their lightweight bout at Meta APEX in Las Vegas. The stoppage came at 2:44 of Round 3.
The fight was competitive with both men having their moments. Silvestre seemed a step ahead, and bloodied McCracken in Round 2. A looping punch floored McCracken midway through the final round, and a glancing hammerfist finished off the job.
The finish got a big reaction out of UFC CEO Dana White and CBO Hunter Campbell.
Sanchez, 24, carved out his reputation on the Mexican regional scene with standout performances for Lux Fight League. Tuesday's win was the fourth knockout of his pro career. He has five career submissions as well.

#sanchez #fight #Career

Uber (UBER) has been managing to pull off something rare in the AI era. It has kept its AI spending flat since April, even as usage inside the company has skyrocketed. Weekly requests to its AI agents have jumped more than nine times since February, yet the total bill hasn't followed. On a per-use basis, costs have fallen sharply. The cost of every thousand requests is down about 34% from its April peak, and a single session now costs 52% less than it did in June. Uber got there by routing simple tasks to cheaper AI models and saving the expensive ones for tougher jobs. It also caps how much each session can use and shows engineers what their AI use is costing in real time.
For investors, here's why all of this matters. Uber blew its entire 2026 AI budget in four months before tightening up. Its net margin slipped from 27% to 17.3% in a year, and the stock fell after its last earnings report as the market worried about those very margins. On top of it, Uber is about to spend over $10 billion on self-driving cars. So the company potentially saving significantly on costs is precisely what investors needed to hear. AI agents now account for more than 70% of Uber's code-change submissions, and engineers run over 30,000 agent tasks a day. Management says this lets it slow hiring while doubling the code each engineer produces.
Wu-Tang Clan Member Raekwon Is a Palantir 'OG,' Visiting Headquarters 16 Years After Receiving His Custom PLTR Jacket
Tesla Stock Could Benefit as Trump Locks Down the U.S. Power Grid
Tesla Just Killed Its Solar Roof After Years of Struggling to Scale. What It Means for TSLA Stock.

#Stock #years

ONE Championship returns to U.S. primetime when ONE Fight Night 47: Stamp vs. Flores on Prime Video airs live from Bangkok's legendary Lumpinee Stadium this Friday, September 4.
Nine action-packed matchups across Muay Thai, MMA, and submission grappling wrap up the world's largest martial arts organization's triple-header weekend, which opens with The Inner Circle 29 and ONE Friday Fights 169.
From a former multi-sport ONE World Champion looking to make a statement to a pair of hungry newcomers making their promotional debuts, here are five reasons fans should circle this stacked card.
The only three-sport ONE World Champion returns to action in the main event of ONE Fight Night 47, chasing a second straight win after recovering from an injury sustained months after she made history by capturing atomweight MMA gold.
In her last outing at The Inner Circle 20, Stamp Fairtex edged Cynthia Flores via split decision for a 15th win under the ONE spotlight. It was far from her usual dominant self after a tough opening round, but the Thai megastar, who also held the ONE Muay Thai and Kickboxing World ***** les at atomweight, tapped into her world-class striking pedigree to turn the tide and get her hand raised.

#flores #Friday

The polls are open!
It's time to vote for the Halifax Health Volusia-Flagler Boys Athlete of the Week for the week of Aug. 24-29.
Last week, Spruce Creek golfer Peyten Patel captured the honors, claiming 60% of the votes. The junior tied teammate Carson Perry for first in the Hawks' nine-hole victory over Father Lopez. Patel fired a one-under-par 35 with two birdies.
The Daytona Beach News-Journal gathers nominees for upcoming polls from across the area via email at cvinelusatodayco.com. Please send a player's name, school and notable statistics for a given week. Submissions are due no later than 8 a.m. every Monday.
To round out the ballot, our staff also picks athletes from scores and stats posted online or submitted by local coaches. Athletes for all in-season sports, except football, are eligible. The News-Journal recognizes the local gridiron stars with our weekly game ******* story.

#local

The polls are open!
It's time to vote for the Halifax Health Volusia-Flagler Girls Athlete of the Week for the week of Aug. 24-29.
Last week, Mainland volleyball player Seyahna Sampson captured the honors, claiming 42% of the votes. The sophomore produced 25 kills, 27 digs and seven blocks against Seabreeze, Matanzas and Deltona.
The Daytona Beach News-Journal gathers nominees for upcoming polls from across the area via email at cvinelusatodayco.com. Please send a player's name, school and notable statistics for a given week. Submissions are due no later than 8 a.m. every Monday.
To round out the ballot, our staff also picks athletes from scores and stats posted online or submitted by local coaches. Athletes for all in-season sports, except football, are eligible. The News-Journal recognizes the local gridiron stars with our weekly game ******* story.

#week

As sports betting continues to proliferate, college football is taking more steps aimed at minimizing inside information.
Via the **** ociated Press, the Big Ten announced on Friday that it will expand its requirement to submit player availability reports from one per week to four.
The rule, which applies only to in-conference games, mandates the submission of a report on each of the three days before a game, with a final report provided on game day.
The midweek reports require teams to identify players as probable, questionable, doubtful, out, or out for the first half. On game day, the categories will be game-time decision, out, or out for the first half.
The existence, and misuse, of inside information regarding player injuries continues to be one of the biggest potential sources of betting scandals. With more information provided to the public, less information will be private — and less information will be available to provide the basis for wagering by those who have access to it.

#game #inside

Rei Tsuruya looked like the biggest favorite of the UFC Fight Night 286 card against Kevin Borjas.
Tsuruya (12-1 MMA, 3-1 UFC) dove for Borjas' (11-6 MMA, 2-5 UFC) legs and took him down immediately to start the flyweight bout. He controlled his foe on the ground with ease and took the back to score the rear-naked choke submission at the 4:14 mark of Round 1 in Saturday's bout at Shanghai Oriental Sports Center in China.
Check out the video of Tsuruya's finish below (via X):
After losing to current UFC flyweight champion Joshua Van at UFC 313, Tsuruya rebounded with back-to-back first-round submissions. The 24-year-old **** anese fighter called for a ranked opponent in his post-fight interview with Brendan Fitzgerald
Rei Tsuruya def. Kevin Borjas via submission (rear-naked choke) – Round 1, 4:14

#kevin #fight #bout

Uncrowned has UFC Shanghai live results, round-by-round updates, highlights and start time for the Umar Nurmagomedov vs. Song Yadong fight card on Saturday at the Oriental Sports Center in Shanghai, China. In the main event, top UFC bantamweight contenders Umar Nurmagomedov and Song Yadong collide in a pivotal five-round showdown.
Nurmagomedov (20-1) enters his second UFC main event on the heels of back-to-back decision wins over Mario Bautista and Deiveson Figueiredo. The 30-year-old's lone career defeat came in his first UFC ******* le shot against then-champion Merab Dvalishvili in January 2025.
Song (23-9-1, 1 NC) returns to action after scoring a submission win over Figueiredo in May. The 28-year-old Chinese contender has won two of his past three fights, sandwiching victories over Figueiredo and former champion Henry Cejudo around a decision loss to Sean O'Malley.
UFC Shanghai starts at 3 a.m. ET with a seven-fight preliminary card on Paramount+. The six-fight main card kicks off at 6 a.m. ET on Paramount+.
Follow along with Uncrowned's live UFC Shanghai results, highlights and live blog below, including round-by-round play-by-play for the main card.

#umar

The Professional Fighters League continues to build its upcomingevent, scheduled for Oct. 16 in Chicago.

The card will be headlined by an undisputed women's flyweight ******* lefight between LizCarmouche and JenaBishop. The bout is a rematch of the 2025 PFL women's flyweighttournament final, which Carmouche won by knockout.

Earlier this week, the promotion added a heavyweight matchupbetween DenisGoltsov and MaxwellDjantou Nana. An intriguing bantamweight contest has now joinedthe lineup.
Promotion officials confirmed to Sherdog that SarvarjonKhamidov (17-1) will face Rafaeldo Nascimento (13-3).

Khamidov is coming off a second-round submission victory over PFLtournament finalist JustinWetzell in June. The contest marked Khamidov's first appearanceof 2026.

A veteran of BellatorMMA and the PFL, Khamidov has steadily advanced through thebantamweight division.

Do Nascimento, a Legacy Fighting Alliance vet, also enters the matchup followinga win. In his PFL debut, he upset LewisMcGrillen-Evans by second-round submission.

#nascimento #khamidov #PROMOTION #professional

On August 13, Nektar Therapeutics (NASDAQ:NKTR) held its second-quarter earnings call and laid out where its lead drug candidate stands after years of development. Rezpegaldesleukin, known as rezpeg, is now enrolling patients in Phase 3 trials for two separate autoimmune conditions, atopic dermatitis and alopecia areata. Management framed the quarter around two numbers that matter most to investors right now: a $1.02 billion cash balance that provides a runway into 2028, and a drug program that finally has late-stage data on the calendar.
Nektar's Phase 3 program for atopic dermatitis, called ZENITH AD, began randomizing patients in July 2026 across two pivotal studies, each enrolling 510 adolescent and adult patients. A third study in patients who have already tried other treatments is set to start by the end of September 2026. Management expects top-line data from the first studies in mid-2028, with a Biologics License Application submission to follow in 2029 if results hold up. After an end-of-Phase 2 meeting with the FDA, Nektar also finalized a single registrational Phase 3 study for alopecia areata, called ZENITH AA, which will enroll 850 patients and use a SALT score of 20 or less at week 52, meaning 80% or more scalp hair coverage, as its primary endpoint.
The case for rezpeg goes beyond trial design. CEO Howard Robin noted that roughly 15 million people in the U.S. have moderate to severe atopic dermatitis, and fewer than 10% currently get a systemic therapy, leaving room for the market itself to grow. He also pointed out that about half of patients on IL-13 drugs such as Dupixent either stop responding or never respond at all. In alopecia areata, where JAK inhibitors carry boxed warnings that keep many dermatologists away, the market for approved treatments is still projected to reach $5 billion by 2033. Nektar's own market research found that 150 of 151 physicians surveyed preferred rezpeg's short-lived injection site reactions over the longer-lasting conjunctivitis tied to current options, a result management used to argue rezpeg could compete across first, second, and third-line patients.
None of this comes cheap. Nektar's operating loss widened to $42.3 million in the second quarter, up from $36.2 million a year earlier, and the net loss came in at $40.6 million, or $1.23 per share. Research and development spending is set to climb further, with full-year guidance now at $210 million to $230 million as the Phase 3 programs and manufacturing activities ramp up. The company's only revenue right now is $10.1 million in noncash royalty income, down from $11.2 million a year ago, and full-year revenue guidance tops out at $45 million. That gap between spending and revenue is why Nektar leaned on a public stock offering that raised $373.8 million in gross proceeds in April 2026, a move that keeps the lights on but also dilutes existing shareholders.

#quarter

MOUNT PLEASANT, S.C. (WCBD) – Organizers of the Cooper River Bridge Run have unveiled the official design for the race's 50th anniversary event, set for spring 2027.
The winning artwork, created by Chuck Jones, was revealed Wednesday during a special event at Alhambra Hall in Mount Pleasant featuring Storm Team 2 Chief Meteorologist Rob Fowler.
Selected after months of submissions, public voting and judging, Jones' design commemorates the milestone anniversary by featuring the Arthur Ravenel Jr. Bridge alongside the two former Cooper River spans, the John P. Grace Memorial Bridge and the Silas N. Pearman Bridge.
Race organizers said the design will be featured on official race merchandise and promotional materials, including T-shirts, posters and billboards leading up to the event.
The 50th annual Cooper River Bridge Run is scheduled for April 3, 2027.

#design #Event #organizers #race

LLY posted 48% revenue growth and controls 6 in 10 U.S. obesity prescriptions, while NVO cut 12,000 employees and saw gross margins fall to 78%.
Retatrutide hit Phase 3 endpoints with weight loss approaching bariatric surgery levels, with Lilly targeting a U.S. BLA submission in Q1 2027.
Act now: the ***** yst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn't make the cut. Grab the names FREE today.
Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) both reported Q2 2026 results in early August, and the split screen was jarring.
Lilly delivered 48% revenue growth and raised guidance. Novo defended a shrinking U.S. business with price cuts, layoffs, and a fresh round of pipeline impairments. Same week, same category, opposite momentum.

#lilly #NYSE #same #NVIDIA

Everton started their cup play against Preston North End after the 40 mile drive down the M58 and up the M6. David Moyes ended his playing career at Preston and also started his managerial career before Everton came looking for someone to save them from the drop in 2002. A lot has happened since then but what has not changed is the fact that neither team have won silverware since then and today was another step in that journey. On a purely selfish note, I am heading home to Liverpool in September and would love to see a round three match with the Mighty Blues playing under the lights!
David Moyes went with a strong side to take on Preston. Jarrad Branthwaite and Hayden Hackney were given the night off with Michael Keane and James Garner taking their places. A big surprise to see O'Brien on the bench. Tyler Dibling was given another chance to shine on the right wing with Ndiaye moving to his favoured left.
Everton advanced to the third round of the Carabao Cup following a dominant victory over Preston North End, highlighted by a clinical hat-trick from Thierno Barry. After a closely contested first half, Everton pushed forward and eventually forced Preston into submission.
The match began with a warm reception for former manager David Moyes, which set a lively atmosphere that energized the travelling Evertonians. While Preston looked to sit back in a resilient low block and strike on the counter-attack through Delano Burgzorg and Adam Armstrong, Everton safely neutralized those early threats. The Toffees dictated the tempo through key involvements from Iliman Ndiaye, Tyler Dibling, and Kiernan Dewsbury-Hall, despite initially struggling to breach Preston's crowded defensive line.
The deadlock was finally broken when Dewsbury-Hall lobbed a precise ball over the top to Vitaliy Mykolenko, who slid a low cross into the middle for Thierno Barry to tap past goalkeeper Nichols. The Evertonians were in full voice. "Oh, Tierno Barry, oh, Tierno Barry!"

#everton

By Waylon Cunningham
Aug 26 (Reuters) - Taylor Farms, the produce company at the center of a U.S. cyclospora outbreak, frequently failed to submit federally required workplace injury logs in recent years, including for at least four facilities where workers suffered fatal or otherwise serious injuries, a Reuters review of federal records found.
Over the ‌past five years, five to seven Taylor Farms facilities filed the annual report within the following year, with some showing injury rates above industry averages, while others ‌recording below-average rates. From 2021 to 2025, at least 17 facilities required such filings based on the number of employees and nature of the work, according to a review of intermittent U.S. Occupational Safety and Health Administration inspection filings.
The figures indicate an overall reporting rate well below the industry average of 78%, based on Reuters calculations of 2023 census numbers and the latest OSHA data. OSHA did not respond to questions about Taylor Farms' lower reporting rate.
Reporting gaps, which Taylor Farms acknowledged to Reuters, make it difficult for the public to ****** s the workplace safety record of the California-based company, according to some workplace safety watchdog groups. OSHA has said, in rulemaking documents, memos and public releases, that electronic submission of these logs allows the agency to focus its enforcement efforts and that it ‌is important for the public to have access to them.

#taylor #farms